The European Commission said on Wednesday it had cleared generic drug maker Mylan’s planned takeover of Ireland-based Perrigo Co.
The Commission said in a statement that the proposed acquisition would not raise competition concerns, because the parties’ activities are largely complementary, Mylan being one of the main European producers of prescribed generic drugs and Perrigo specialised in selling over-the-counter drugs.
Mylan had been at the centre of a three-way takeover battle, with Perrigo having rejected a sweetened $34 billion offer, and Mylan seeking to fend off a takeover by Israel-based Teva Pharmaceutical Industries, the world’s largest generic drug maker.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI